ACXP
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Acurx Pharmaceuticals received FDA conditional acceptance and USPTO trademark allowance for the brand name of ibezapolstatAug 17, 2026
- Japan and Mexico granted Acurx Pharmaceuticals new patents covering DNA polymerase IIIC inhibitor antibioticsAug 12, 2026
- FDA provided additional regulatory guidance for Acurx's ibezapolstat program, including the potential for a single Phase 3 registration trialAug 3, 2026
- USPTO granted Acurx Pharmaceuticals patent for DNA Polymerase IIIC inhibitorsFeb 2, 2026
- Australian Patent Office grants Acurx patent for DNA polymerase IIIC inhibitorsOct 9, 2025